Our functional epigenomics strategy also suggests novel MEOX2-GLI1 transcriptional axis signaling is involved in resistance to the cancer drug cisplatinum in a dose-dependent manner, as previously proposed for lung cancer [21]. The gene discussed is GLI1; the disease is lung carcinoma.